Medtronic has received CE mark approval for its CoreValve delivery system with AccuTrak Stability Layer for transcatheter aortic valve implantation (TAVI) following global launch of the system.

AccuTrak’s technology builds upon the CoreValve system and allows physicians to achieve enhanced control and accuracy in the deployment of the CoreValve device.

Medtronic said that the CoreValve and AccuTrak are not yet available in the US, Canada or Japan for investigational or commercial sale or use.

The German Heart Centre in Munich Cardiovascular Surgery director and professor Rudiger Lange said that the AccuTrak stability layer is a valuable advancement for CoreValve, which already offers a self-expanding design to control the positioning and release of the valve.

“This system makes it easier to precisely position the CoreValve device, which can be important to achieving positive procedure outcomes and the increased accuracy and control with the new delivery system may also make it even easier to train physicians to perform TAVI procedures,” Lange said.

Medtronic Structural Heart division vice president and general manager John Liddicoat said that AccuTrak is an exciting advancement that leverages proven technology and expertise from Medtronic’s innovative cardiovascular portfolio for the improvement of TAVI.

“This is the first of many planned CoreValve system enhancements that we expect will simplify the procedure, enhance clinical outcomes and expand patient access,” Liddicoat said.